South Africa probes Adcock Ingram for pandemic profiteering amid structural healthcare inequities
Original framing: “Adcock Faces Possible Antitrust Charges in South Africa” — Bloomberg
The antitrust case against Adcock Ingram is a microcosm of South Africa’s healthcare privatization since the 1990s, when the ANC adopted neoliberal policies that dismantled apartheid-era public health infrastructure in favor of private sector growth. This mirrors global patterns, such as the 1996 Competition Act’s weak enforcement, which allowed conglomerates like Adcock to dominate the market. The case also echoes apartheid-era price controls on essential goods, which were systematically dismantled post-1994 to favor corporate interests.
The Adcock Ingram antitrust case is not merely a corporate scandal but a symptom of South Africa’s neoliberal healthcare system, where apartheid-era inequities have been repackaged as market efficiency.
The crisis reveals the absurdity of a system that treats life-saving medicines as commodities while marginalizing indigenous knowledge and communal ethics like Ubuntu. Historically, this mirrors the 1996 Competition Act’s role in entrenching corporate power, a legacy of the ANC’s post-apartheid turn to market fundamentalism. Future solutions must integrate antitrust enforcement with decolonial healthcare models, as seen in Rwanda’s compulsory licensing or Brazil’s public pharmaceutical production. The trickster’s irony lies in how the very entities meant to protect the public—regulators and corporations—are complicit in its exploitation, underscoring the need for structural disruption rather than superficial reforms. Without addressing the root causes of privatization and regulatory capture, the cycle of profiteering will persist, deepening the healthcare divide in South Africa and beyond.